INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 202 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is 1.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,106,809 | +131.9% | 383,323 | +38.3% | 0.00% | 0.0% |
| Q2 2023 | $3,064,804 | -16.2% | 277,107 | +1.8% | 0.00% | 0.0% |
| Q1 2023 | $3,655,538 | +9.9% | 272,192 | +1.2% | 0.00% | 0.0% |
| Q4 2022 | $3,327,468 | -3.8% | 268,995 | +8.5% | 0.00% | 0.0% |
| Q3 2022 | $3,460,000 | +0.8% | 248,015 | -0.2% | 0.00% | 0.0% |
| Q2 2022 | $3,433,000 | -20.3% | 248,607 | -6.1% | 0.00% | 0.0% |
| Q1 2022 | $4,308,000 | -4.9% | 264,762 | -4.8% | 0.00% | 0.0% |
| Q4 2021 | $4,531,000 | +7.0% | 278,147 | -2.5% | 0.00% | 0.0% |
| Q3 2021 | $4,236,000 | -29.3% | 285,204 | -5.0% | 0.00% | 0.0% |
| Q2 2021 | $5,995,000 | -9.3% | 300,207 | +4.8% | 0.00% | 0.0% |
| Q1 2021 | $6,609,000 | -10.4% | 286,341 | -4.1% | 0.00% | 0.0% |
| Q4 2020 | $7,374,000 | -42.1% | 298,531 | -2.9% | 0.00% | -66.7% |
| Q3 2020 | $12,744,000 | -22.2% | 307,426 | -10.0% | 0.00% | -25.0% |
| Q2 2020 | $16,374,000 | -22.4% | 341,767 | +2.0% | 0.00% | -33.3% |
| Q1 2020 | $21,104,000 | -48.6% | 335,203 | +1.1% | 0.01% | -33.3% |
| Q4 2019 | $41,097,000 | +85.0% | 331,637 | -0.9% | 0.01% | +80.0% |
| Q3 2019 | $22,219,000 | -4.9% | 334,817 | +14.0% | 0.01% | -16.7% |
| Q2 2019 | $23,376,000 | -22.7% | 293,776 | +8.6% | 0.01% | -14.3% |
| Q1 2019 | $30,254,000 | +13.0% | 270,467 | +1.8% | 0.01% | -12.5% |
| Q4 2018 | $26,776,000 | -20.7% | 265,661 | -0.6% | 0.01% | 0.0% |
| Q3 2018 | $33,786,000 | +56.2% | 267,381 | +3.7% | 0.01% | +60.0% |
| Q2 2018 | $21,629,000 | +295.9% | 257,755 | +190.3% | 0.01% | +400.0% |
| Q1 2018 | $5,463,000 | +8.3% | 88,800 | +2.9% | 0.00% | 0.0% |
| Q4 2017 | $5,042,000 | +0.9% | 86,311 | +0.2% | 0.00% | 0.0% |
| Q3 2017 | $4,999,000 | -51.4% | 86,129 | +1.3% | 0.00% | -66.7% |
| Q2 2017 | $10,289,000 | +23.0% | 84,983 | +14.9% | 0.00% | +50.0% |
| Q1 2017 | $8,368,000 | -4.9% | 73,990 | -8.6% | 0.00% | -33.3% |
| Q4 2016 | $8,799,000 | -30.1% | 80,983 | +5.9% | 0.00% | -25.0% |
| Q3 2016 | $12,590,000 | +19.5% | 76,494 | +3.6% | 0.00% | +33.3% |
| Q2 2016 | $10,539,000 | +12.2% | 73,854 | +3.6% | 0.00% | 0.0% |
| Q1 2016 | $9,397,000 | -7.6% | 71,284 | +4.7% | 0.00% | 0.0% |
| Q4 2015 | $10,171,000 | -15.4% | 68,096 | -6.0% | 0.00% | -25.0% |
| Q3 2015 | $12,017,000 | -5.5% | 72,452 | +37.5% | 0.00% | 0.0% |
| Q2 2015 | $12,723,000 | -14.8% | 52,705 | -0.5% | 0.00% | 0.0% |
| Q1 2015 | $14,936,000 | +102.9% | 52,958 | +12.2% | 0.00% | +100.0% |
| Q4 2014 | $7,362,000 | -35.2% | 47,191 | -1.6% | 0.00% | -50.0% |
| Q3 2014 | $11,354,000 | -52.6% | 47,972 | -52.6% | 0.00% | -42.9% |
| Q2 2014 | $23,951,000 | -36.9% | 101,221 | -12.1% | 0.01% | -41.7% |
| Q1 2014 | $37,955,000 | +417.3% | 115,091 | +7.1% | 0.01% | +500.0% |
| Q4 2013 | $7,337,000 | +9.4% | 107,465 | +10.7% | 0.00% | 0.0% |
| Q3 2013 | $6,704,000 | +98.5% | 97,114 | +28.9% | 0.00% | +100.0% |
| Q2 2013 | $3,378,000 | – | 75,353 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |